Novartis’ Post

The global incidence of early-onset cancer increased by 79.1%, and early-onset cancer deaths rose by 27.7% from 1990 to 2019, according to a 2023 study in the journal BMJ. Can you be prepared if cancer strikes? Call (246) 231-2045 to learn more.

The global incidence of early-onset cancer increased by 79.1%, and early-onset cancer deaths rose by 27.7% from 1990 to 2019, according to a 2023 study in the journal BMJ. Can you be prepared if cancer strikes? Call (246) 231-2045 to learn more.

Just released on Jama, Nov 28. Opinion on the phase III randomized trial of chemo-immunotherapy vs chemotherapy in first-line rec/met nasopharyngeal cancer (JUPITER-02). Overall, 37% reduction of risk of death at 3 years. To be discussed: - the lack of mainteinance therapy in chemotherapy only arm - the importance of EBV DNA dynamic - no role for PD-L1 expression as predictive factor - less evidence in de novo metastatic pts - applicability in non-endemic settings An important step in the treatment of NPC cancer pts!

Current cancer therapies are dominated by strategies that use systemic drug administration. However, if one looks at the cancer stage at the time of diagnosis, it is clear that a large number of cancers are diagnosed these days at a stage when they are either local or regional. Hence, strategies for local delivery of therapies should become an important tool in cancer treatment. In a recent review in Journal of Controlled Release led by Suyog Shaha and Danika Rodrigues, we summarize and analyze the current clinical landscape of local drug delivery therapies to tumors. #cancertreatment #localdelivery https://lnkd.in/eT7APgfK

EGFR mutations in non-small-cell lung cancer (#NSCLC) are twice as common among Asian patients compared to Caucasian patients, posing a significant management challenge. Two presentations at #ESMOAsia23 provide insights into recent treatment options. The subgroup analysis of Asian patients in the MARIPOSA-2 trial supports the main trial analysis showing a significant improvement in PFS with amivantamab plus chemotherapy compared to chemotherapy alone in patients progressing on osiemrinib. An exploratory analysis of the FLAURA2 trial suggested that the addition of platinum-based chemotherapy to first-line osimertinib did not impact acquired resistance mechanisms and should not influence targeted second-line treatment options. To learn more about this topic, and the challenges ahead in EGFR-mutated #NSCLC, read the # ESMODailyReporter article commented by Antonio Passaro 👉https://ow.ly/CR9B50QeLri

The global incidence of early-onset cancer increased by 79.1%, and early-onset cancer deaths rose by 27.7% from 1990 to 2019, according to a 2023 study in the journal BMJ. Can you be prepared if cancer strikes? Call (246) 231-2045 to learn more.

November is #PancreaticCancerAwarenessMonth. Pancreatic cancer has very poor survival rates. Our scientists are dedicated to researching which genes🧬are involved in this type of cancer and find new approaches to treatment. Our work also aims to transform the landscape for patients with pancreatic cancer by making the most innovative new drugs available to patients as quickly as possible, and ensuring treatments are developed for those cancers that have yet to benefit significantly from modern advances in precision medicine. Learn more⬇️ https://lnkd.in/enhmHwwQ

Analyzing DNA From Pap Smears Could Help Diagnose Ovarian Cancer Early High-grade serous ovarian cancer (HGSOC) is the gynecological cancer with the highest mortality rate, with this trend driven by late diagnosis due to non-specific symptoms in early stages and a lack of early screening methods. Read more on our blog: https://lnkd.in/dc_P-_ii

We focus on creating unique #DARPin solutions for major medical challenges. MP0533 shows our strategy at work against acute myeloid leukemia (#AML), an aggressive cancer with a high relapse rate. MP0533 is a tetra-specific molecule that strongly prefers binding to AML cells over healthy cells through the combined targeting of three surface antigens that are mostly only found together on AML cells. Combined with binding to the immuno-stimulator CD3, the net effect is a powerful directed immune attack with high specificity for AML cells. The goal? Better clearance of AML cells with less risk to healthy cells – a clear match for the medical need in many AML patients today. For more information about MP0533 and our other #cancer therapies in development, see https://bit.ly/46erfgS #biotech

🌟 𝗡𝗲𝘄 𝗥𝗲𝗹𝗲𝗮𝘀𝗲: "𝗪𝗵𝗮𝘁’𝘀 𝗡𝗲𝘄 𝗗𝗼𝗰? 𝗶𝗻 𝗚𝗨 𝗖𝗮𝗻𝗰𝗲𝗿” 🌟 In our latest episode, Prof Emmanuel Seront and Prof Christof Vulsteke provide a detailed analysis of the KEYNOTE-B61 study, a significant leap forward in the treatment of non-clear cell renal cancer, as presented at ASCO. Discover how the combination of lenvatinib and pembrolizumab is setting new standards for patient care, showing promising results beyond its established success in endometrial and clear cell renal cancers. 👇 View all WND GU videos - link in the comments! #MediMix #GUCancer #RenalCancer #OncologyInnovation